Immunitybio is trading 5.23% down at $7.79 on October 26, 2026; no clear company-specific catalyst was identified.

  • The latest company announcement was the October 21 database lock for its ANKTIVA trial, with topline results expected in November; that update does not establish the reason for the drop.
  • Major U.S. indexes were higher, so broad-market weakness does not explain the move.